12:00 AM
 | 
Oct 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aldoxorubicin: Preliminary Phase IIb data

Preliminary data from an open-label, international Phase IIb trial in 82 evaluable patients showed that aldoxorubicin as first-line treatment led to an ORR of 22% (n=58) vs. 0% for doxorubicin (n=24). Specifically, aldoxorubicin led to 13 partial responses plus 27 cases of stable disease compared to 0 partial responses plus 11 cases of stable disease...

Read the full 254 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >